Alecensa (alectinib)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.

Anaplastic lymphoma kinase (ALK) belongs to a family of proteins called receptor tyrosine kinases (RTKs), which are involved in the growth of cells and the development of new blood vessels that supply them. In patients with ALK-positive non-small cell lung cancer (NSCLC), an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion.1

Treatment options for people with ALK+ mNSCLC include therapies called ALK inhibitors that target abnormal ALK proteins. ALK inhibitors work by blocking the abnormal ALK protein responsible for the growth and spread of ALK+ mNSCLC.2

In Bangladesh Alecensa is approved for the following indications.3

  • Alecensa is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

  • Alecensa is indicated for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC who have progressed on or are intolerant to crizotinib.

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh Alecensa is available as
Capsules 150 mg

is the authorized importer and distributor for Roche pharmaceutical medicines in Bangladesh. To meet strict quality and compliance, Radiant maintains temperature controlled supply chain.

To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.


  1. Alecensa European Medicines Agency [Internet; cited 2020, March 17]. Retrieved from

  2. What is ALECENSA® (alectinib) [Internet; cited 2020, March 17]. Retrieved from

  3. Alecensa Product Information _ BD Ro 5424802_November 2021


Alecensa Product Information _ November 2021

Discover more


This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.

ContactLocationslinkedinfacebooktwitterinstagramyoutubePharmacovigilanceAbout RochePharma solutionsRoche careersPersonalised healthcarePrivacy policyLegal statementCookie policy